Latest $18M contract brings New England Research to $105M for pediatric research
Research & Development
Stentys’ Apposition stent goes head-to-head against Medtronic’s Resolute | Studies Roundup
Stentys SA (EPA:STNT) is looking to prove its next-generation Apposition IV stent in a head-to-head study against Medtronic’s (NYSE:MDT) Resolute.
Medtronic’s recalled Fidelis leads fracture after ICD swap, researchers say
Updated June 15, 2012, at 1:15 p.m. with comments from Medtronic.
A common procedure in which surgeons swap out a patient’s implantable cardioverter defibrillator may significantly increase the risk of failure for Medtronic’s (NYSE:MDT) already fracture-prone Sprint Fidelis defibrillator leads, according to a new study.
Imagers seek to “debunk” radiation-exposure cancer concerns
A handful of recent warnings about radiation exposure during medical imaging has device makers eager to distance themselves from the potential cancer risk.
Catalyzed by a study finding in recent years a "boom" in the use of medical imaging, the Medical Imaging & Technology Alliance issued a rejoinder arguing that use has begun to decline and that device makers are actively innovating systems that lower the radiation dose.
Predicting CRT “super-responders” may help better target mild heart failure patients
New data may help doctors better target mild heart failure patients who are more likely to be "super-responders" to cardiac rhythm therapy.
This class of patients exhibits significant improvements in cardiac function with greater survival rates and lower heart-failure related hospitalizations, according to researchers, sometimes becoming symptom-free within as little as 6 months of device implantation.
Weight loss: EndoBarrier effective against obesity and diabetes | Research Roundup
GI Dynamics’ (ASX:GID) EndoBarrier implant proved safe and effective in curbing both obesity and Type II diabetes in a as little as 6 months, according to a study presented at the American Diabetes Assn. meeting in Philadelphia.
Does a robot-assisted prostatectomy cost more?
Robot-assisted prostate surgery may be a profit-sink for hospitals, according to a new study set to be published in the July issue of the journal Urology.
Funding R&D: High prices, overuse a failed strategy
Much has been written about the travails of the pharmaceutical industry. Generic competition is reducing profitability as leading blockbuster drugs like Pfizer’s Lipitor lose patent protection. Biotech generic competition is on the horizon.
EuroPCR: Disappearing stents and bioabsorbable polymers
Disappearing technology had a strong presence at this year’s EuroPCR conference in Paris, with rival device makers demonstrating the safety and efficacy of their next-generation stents.
Elixir Medical unveiled 1st-in-man clinical results for its DESolve fully bioabsorbable drug-eluting scaffold system, a stent made from a proprietary polymer and coated in novolimus. The entire stent is designed to be absorbed by the body in 1-2 years.
EuroPCR: St. Jude’s Enlightn lowers blood pressure faster than rival systems
St. Jude Medical’s (NYSE:STJ) newly cleared Enlightn renal denervation system lowered patients’ blood pressure by twice as much as rival systems in the same amount of time, according to a new study.
Preliminary findings from a study of the Enlightn system found that patients with hypertension saw a 28 point reduction in blood pressure after 30 days.
EuroPCR: Warnings on TAVI in replacing surgically implanted prosthetic valves
Although patients may benefit from having a failed aortic valve prosthetic reinforced via transcatheter aortic valve implantation, researchers warned against making the procedure a common practice.